We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Elucid Stock

Invest in or calculate the value of your shares in Elucid or other pre-IPO companies through EquityZen's platform.

Get Started

Elucid Stock (ELUC)

Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.

About Elucid Stock

Founded

2013

Headquarters

Boston, MA, US

Industries

Software, Artificial Intelligence, Data and Analytics

Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Elucid Press Mentions

Stay in the know about the latest news on Elucid

Elucid receives FDA clearance for PlaqueIQ image analysis software

med-technews • Oct 05, 2024

Kelly Huang Takes Charge at Elucid

mpo-mag • Aug 21, 2024

Elucid Kicks Off Review of its Plaque Analysis Tool

mpo-mag • Aug 19, 2024

Elucid moves to new Boston HQ

massdevice • Jul 24, 2024

Elucid Names Kelly Huang as CEO

businesswire • Jul 22, 2024

Elucid Management

Leadership team at Elucid

President and CTO

Andrew J. Buckler

CCO

Jason Bottiglieri

Locked Features

Join now and verify your accreditation status to gain access to:

  • Elucid current valuation
  • Elucid stock price
  • Available deals in Elucid and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Elucid stock?

Accredited investors can buy pre-IPO stock in companies like Elucid through EquityZen funds. These investments are made available by existing Elucid shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Elucid stock?

Shareholders can sell their Elucid stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."